AMH Handheld Jan 2012 Edition
Overview : AMH Handheld is a downloadable version for Personal Digital Assistants (PDAs) and other Handheld/Mobile devices.
Features:
* Contains over 2,000 pages designed for ease of use on a small screen
* Allows you to browse by chapter or search by generic drug name, brand name, class name, interaction or treatment
* Has intuitive navigation
* Occupies only 4MB of space on your device
BackgroundAMHis the indispensable drug reference for Australian healthcare professionals, with a reputation for independence and accuracy second to none. It is continuously updated by an expert editorial team of pharmacists and medical practitioners. It has a distinguished Editorial Advisory Board and reviewers drawn from many of Australia’s leading educational and medical institutions.Each chapter contains common information that provides a framework for the reader to use the individual drug monographs. These monographs are organised within chapters, each of which represents an organ system and the major therapeutic drug classes within the system.Comparative information about different drugs within the same class, or other drugs for the same indication, is highlighted so that the reader can make an informed choice about the most appropriate drug to use.Since a publication of this size cannot be exhaustive, the writers and members of the Editorial Advisory Board have included only that material which they consider to be the most relevant and useful for rapid reference by the busy health professional.AMHcontains no drug company advertising. In fact, in line with our strict policy of total independence, we do not accept any commercial advertising or sponsorship, or direct editorial input, from any outside sources.Instead,AMHeditors critically review information and evidence from a wide range of resources, ensuring a comprehensive and current overview. For example,AMH first raised questions over cardiovascular safety with selective NSAIDS (COX-2 inhibitors) in our January 2002 edition - over two years before the Rofecoxib (Vioxx) ban and subsequent ongoing debate.2010 Edition:The 2010 edition contains new monographs on medicines marketed during 2009, including alfuzosin, cilostazol, dabigatran, desvenlafaxine, etoricoxib, methylnaltrexone, rivaroxaban, triptorelin, everolimus, etravirine, sugammadex, dutasteride and doripenem.Other important changes include updating the content that describes the uses for these new medicines to reflect changed evidence and practice. These include prevention of venous thromboembolism (dabigatran, rivaroxaban), benign prostatic hyperplasia (alfuzosin, dutasteride) and peripheral vascular disease (cilostazol).We also incorporate advice from new practice guidelines, hospital protocols, local and international literature, and regulatory sources. For example, in advance of changes to Australian product information, we have improved our dosage and drug interaction information for colchicine, to reduce its significant risk of toxicity. This was based on new FDA data providing evidence that doses much lower than those traditionally used are effective and safer.
Structure
* Chapters: Bring together treatment reviews and related drugs and drug classes. Nested documents keep common information together, enable comparisons and reduce repetition; cross references link relevant information. Practice points give tips and advice.
* Treatment: Summarises evidence and clinical practice for a condition and gives context for drug treatment. Discusses and compares the role of different classes and individual drugs in treating the condition.
* Drug Class: Cross refers to Treatment(s). Provides information common to all members, eg mode of action, contraindications, adverse effects. Comparative information describes differences between class members.
* Drug Monograph: If a drug is a class member it cross refers to Class for essential information common to the group. If not in a class it may refer to Treatment(s). Contains specific information for individual drugs, eg dosage, indications and products.
* Appendices: Include drug interactions, electrolytes, laboratory reference ranges and contact information
Philosophy:The philosophy of the AMH is to use the best available evidence to support prescribing and dispensing recommendations. The purpose of the AMH is twofold:
* To provide a readily accessible, concise, up-to-date source of independent drug information to facilitate effective, rational, safe and economical prescribing.
* To provide an educational tool for practitioners and students
Features and Benefits
* Clinically Relevant:AMH reflects Australian best practice. Using a best-available evidence approach,AMH editors appraise Australian and international sources, including Cochrane, Clinical Evidence, ACHRP CCHOTA assessments. Our content is reviewed by Australian experts and practicising health professionals from across the country (specialists, general practitioners, nurses, pharmacists).
* Quick and Easy to Use: Arranged according to organ system and therapeutic use. Edge-of-page tags provide instant access to sections. User-friendly index - look up disease, drug class, generic or brand name of medicine. Substantial cross referencing assists navigation.
* Safety and Efficacy: We include only clinically important drug interactions, with practical advice on management. Adverse effects are listed according to frequency. Monitoring advice for best outcome. Advice for patients, in everyday language. Special populations including children and older people.
* Save Time and Keep Up-To-Date: Accurate, concise and relevant drug and therapeutics information. Summaries of new evidence and areas of therapeutic uncertainty. Help in assessing the balance between efficacy and safety. Comparisons of treatments, drug classes and differences between members of a drug class.
Requirements : WM2003-WM6.5
Download:
Reg with any key http://uploading.com/files/mf3982ba/AMHHandheld.Jan.2012.crk_igorca.cabPlease Post Your Suggestions.
Read More!
Posts
